Torgeir Vaage joins Aqilion as Chief Financial Officer

Written by: Pharmiweb editor
Published On: 21 May 2020

AQILION AB announced today that Torgeir Vaage has joined the company as Chief Financial Officer (CFO). Torgeir will be responsible for the finance department with the overarching responsibility for the company's financial management. He will also assist the CEO in matters concerning strategy and funding of operations.

In recent years, Torgeir Vaage has worked in Denmark and Norway as CFO and CEO for several small biotech companies with a focus on pharmaceuticals and in close collaboration with venture capital companies such as Sarsia Seed, Novo Seed and Norsk Innovasjonskapital. Before his interest in biotechnology companies – and then primarily in companies in early phase – brought him to the life science industry, Torgeir spent six years as a senior analyst and partner at ABG Sundal Collier. Prior to that, he worked as a senior capital analyst at Handelsbanken and management consultant for AT Kearney in Oslo. Torgeir holds a MSc in business and economics from the Norwegian School of Economics (NHH) and a PhD in business administration from the University of California, Berkeley.

“We are pleased to welcome Torgeir Vaage to Aqilion. His extensive experience and knowledge of financial analysis, development processes and funding on an international market combined with his operational experience from business development of biotech companies with a focus on innovative new medications will strengthen our both internally and in external collaborations,” says Sarah Fredriksson, CEO of AQILION AB.

For more information, please contact
Sarah Fredriksson
CEO, AQILION AB
+46 (0)70 261 4575
sarah.fredriksson@aqilion.com

About AQILION AB
Aqilion is a Swedish life science company that identifies unique ideas that have the potential to become new medications and refines them into commercially interesting projects. Our projects are based on solid scientific grounds where we can clearly understand the underlying biology, clinical relevance and patient benefit. We focus on indications within inflammation at the interface of oncology and immunology, where we see a great future need, good potential for innovation and a clear interest in the market. Our customers represent the next step in the care chain: the pharmaceutical and biotech industries. Aqilion has its headquarters in Helsingborg, Sweden. Please visit www.aqilion.com.